CorVascular and Vasamed Enter Into Collaboration and Distribution Agreement for Peripheral Vascular Diagnostic Systems

October 12, 2015—CorVascular Diagnostics, LLC, which designs and distributes peripheral vascular diagnostic solutions, announced that it has entered into a collaboration and distribution agreement with Vasamed Incorporated, a producer of devices, software, and services for assessing and managing hemodynamic health. Vasamed’s SensiLase PAD-IQ provides dependable, reproducible measurement of tissue perfusion of the extremities, particularly in patients who have combined peripheral arterial disease (PAD) and diabetes.

Under the companies’ agreement, CorVascular becomes the exclusive distributor of the PAD-IQ system in the United States hospital market and the Vasamed sales force will collaborate with the CorVascular sales force to market CorVascular's products. 

A key component of the arrangement is the joint selling of a unique integrated vascular diagnostics product suite throughout all segments of the United States market.

The SensiLase PAD-IQ is an alternative to transcutaneous oximetry for wound prediction and amputation level determination. The SensiLase PAD-IQ system provides a fully automated and quantitative evaluation of microcirculatory perfusion in the skin. PAD-IQ measures skin perfusion using a laser Doppler sensor and a pressure cuff to evaluate reactive hyperemia.

CorVascular integrates the PAD-IQ directly onto the Falcon ProV series (Viasonix Ltd.) to aim to provide a faster, more accurate, and more cost-effective equivalent to transcutaneous oximetry. By integrating PAD-IQ with the Falcon PVD system, CorVascular has created a one-of-a-kind complete solution for assessing macro and microcirculation, stated the company.